Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists

Publication History

1. Developed February 2006.
2. Revised September 2018; September 2016; June 2015; October 2013; December 2011; February 2010; January 2010; August 2006; May 2006.

Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document.

Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage.

Prepared by:

- Drug Information Service, UT Health San Antonio.
- The College of Pharmacy, The University of Texas at Austin.
1 Dosage [*]

1.1 Adults

Incretin hormones such as glucagon-like peptide (GLP-1) are peptides released from gastrointestinal tract cells in response to food ingestion that stimulate glucose-dependent insulin release from the pancreas, decrease glucagon production, and slow gastric emptying. Incretin mimetics, also known as GLP-1 agonists, are FDA-approved as adjunct therapy to diet and exercise to improve glycemic control in adult type 2 diabetics. GLP-1 agonists are not recommended for use as first-line therapy in type 2 diabetes mellitus due to development of malignant thyroid C-cell tumors in rats; these compounds should be used in diabetic patients only when the therapeutic benefits exceed treatment risks.

GLP-1 agonists should not be administered to patients:
- with type 1 diabetes
- experiencing diabetic ketoacidosis
- receiving prandial insulin therapy
- with a history of pancreatitis
- experiencing hypersensitivity reactions to exenatide or its components
- with severe gastrointestinal disease, including gastroparesis

GLP-1 agonist recommended dosages are summarized in Table 1. Patient profiles containing prescriptions with GLP-1 agonist dosages that exceed these recommendations will be reviewed.

Table 1. Adult GLP-1 Agonist Maximum Recommended Dosages in type 2 Diabetes Mellitus

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosage Form/ Strength</th>
<th>Maximum Recommended Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dulaglutide (Trulicity®)</td>
<td>extended-release SC solution; 0.75/0.5 mL, 1.5/0.5mL as single-dose pens or pre-filled syringes</td>
<td>1.5 mg once weekly at any time of day with or without meals</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosage Form/ Strength</td>
<td>Maximum Recommended Dosage</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>exenatide (Byetta®)</td>
<td>regular-release SC solution; 5 mcg/0.02 mL pen, 10 mcg/0.04 mL pen*</td>
<td>5 mcg SC twice daily initially within 60 minutes prior to the morning and evening meals, or prior to the two main meals of the day spaced six hours or more apart; dose may be increased to 10 mcg twice daily prior to the morning and evening meals (or the two main meals of the day, spaced six hours or more apart) after one month of therapy based on clinical response</td>
</tr>
<tr>
<td>Exenatide (Bydureon®)</td>
<td>extended-release SC suspension; 2 mg/0.65 mL mixed in syringe; 2 mg/0.65 mL pen*</td>
<td>2 mg once every 7 days (weekly) at any time of day, with or without meals</td>
</tr>
<tr>
<td>Liraglutide (Victoza®)</td>
<td>SC solution; multi-dose pen (18 mg/3 mL) that delivers 0.6 mg, 1.2 mg, or 1.8 mg</td>
<td>1.8 mg/day at any time of day with or without meals</td>
</tr>
<tr>
<td>Lixisenatide (Adlyxin™)</td>
<td>SC solution; 150 mcg/3 mL (starter pen) delivers 14 doses of 10 mcg; 300 mcg/3 mL (maintenance pre-filled pen) delivers 14 doses of 20 mcg</td>
<td>20 mcg/day at any time of day with or without meals</td>
</tr>
<tr>
<td>Semaglutide (Ozempic®)</td>
<td>SC solution; multi-dose pen available as either 0.25 mg for therapy titration (2 mg/1.5 mL) or 0.5 mg per dose (2 mg/1.5 mL) - package of 1 pen to deliver 6 weeks of therapy (4 weeks titration and 2 weeks of 0.5 mg dose); or 1 mg per dose (2 mg/1.5 mL) – package size of 2 pens to deliver 4 weeks of therapy</td>
<td>0.25 mg³ SC once weekly x 4 weeks, then titrate upward to 0.5 mg SC once weekly; if glycemic control not achieved, may titrate to a maximum of 1 mg SC once weekly</td>
</tr>
</tbody>
</table>

SC = subcutaneous
*each exenatide regular-release pen provides 60 doses of medication
+each exenatide extended-release pen is single-use pen; supplied in carton of 4 pens
³0.25 mg semaglutide dose is for therapy titration only – does not provide glycemic control
1.2 Pediatrics

GLP-1 agonists are not recommended for use in children as safety and efficacy in pediatric patients have not been established.

2 Duration of Therapy

GLP-1 agonists are indicated for the management of type 2 diabetes mellitus and may be continued indefinitely, as control of blood glucose is a chronic, lifelong process.

3 Duplicative Therapy [*]

Adjunctive administration of multiple GLP-1 agonists is not recommended due to increased risk for adverse events with no additional therapeutic benefit. Exenatide regular-release should be discontinued prior to initiating exenatide extended-release therapy. Patient profiles containing prescriptions for multiple GLP-1 agonists will be reviewed.

4 Drug-Drug Interactions [*]

Patient profiles will be assessed to identify those drug regimens which may result in clinically significant drug-drug interactions. Drug-drug interactions considered clinically relevant for GLP-1 agonists are summarized in Table 2. Only those drug-drug interactions identified as clinical significance level 1 or those considered life-threatening which have not yet been classified will be reviewed.
<table>
<thead>
<tr>
<th>Target Drug</th>
<th>Interacting Drug</th>
<th>Interaction</th>
<th>Recommendation</th>
<th>Clinical Significance Level*</th>
</tr>
</thead>
<tbody>
<tr>
<td>antidiabetic agents</td>
<td>fluoroquinolones</td>
<td>adjunctive administration may result in blood glucose disturbances and increased risk for hyper- or hypoglycemia due to an unknown mechanism</td>
<td>closely monitor blood glucose levels and adjust antidiabetic doses as needed; doses may also require adjustments with fluoroquinolone discontinuation</td>
<td>major (DrugReax) 3-moderate (CP)</td>
</tr>
<tr>
<td>antidiabetic agents</td>
<td>somatostatin analogues (SAs) (e.g., octreotide, pasireotide)</td>
<td>concurrent use may impair glucose regulation as SAs inhibit insulin and glucagon secretion; substantially increased blood glucose levels may result</td>
<td>monitor closely for changes in blood glucose control before and throughout SA therapy; adjust antidiabetic doses as needed</td>
<td>major (DrugReax) 2-major (CP)</td>
</tr>
<tr>
<td>exenatide</td>
<td>warfarin</td>
<td>concurrent administration may result in increased international normalized ratio (INR), sometimes with associated bleeding; mechanism unknown</td>
<td>closely monitor for changes in INR and bleeding with exenatide/warfarin drug combination</td>
<td>moderate (DrugReax) 3-moderate (CP)</td>
</tr>
<tr>
<td>GLP-1 agonists</td>
<td>gastric stimulants (e.g., metoclopramide, tegaserod)</td>
<td>concurrent administration may attenuate pharmacologic effects due to competing effects from both agents</td>
<td>monitor blood glucose levels and adjust antidiabetic doses as needed</td>
<td>3-moderate (CP)</td>
</tr>
<tr>
<td>GLP-1 agonists</td>
<td>insulin secretagogues (e.g., sulfonylureas, insulin)</td>
<td>adjunctive administration may lead to increased hypoglycemia due to additive glucose-lowering effects</td>
<td>avoid use, if possible; if combined use needed, adjust insulin doses and closely monitor blood glucose levels</td>
<td>major, moderate (DrugReax) 2-major, 3-moderate (CP)</td>
</tr>
<tr>
<td>Target Drug</td>
<td>Interacting Drug</td>
<td>Interaction</td>
<td>Recommendation</td>
<td>Clinical Significance Level*</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>GLP-1 agonists</td>
<td>oral contraceptives (OCs)</td>
<td>concurrent administration may reduce OC serum levels and reduce efficacy as GLP-1 agonists delay gastric emptying; also, estrogens and progestins impair glucose tolerance</td>
<td>use cautiously together; administer OCs at least 1 hour before GLP-1 agonists and monitor for glycemic control</td>
<td>lixisenatide – major (DrugReax) 3-moderate (CP)</td>
</tr>
<tr>
<td>GLP-1 agonists</td>
<td>oral medications with hypoglycemic effects (e.g., oral antidiabetic agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, fibric acid derivatives, salicylates, sulfonamide antibiotics)</td>
<td>concomitant administration may result in enhanced hypoglycemic pharmacologic and adverse effects</td>
<td>monitor blood glucose levels closely and adjust dosages as necessary if drug combination required to minimize excessive hypoglycemia and associated adverse events</td>
<td>3-moderate (CP)</td>
</tr>
<tr>
<td>GLP-1 agonists</td>
<td>oral medications that slow gastrointestinal motility (e.g., opiate agonists, tricyclic antidepressants, antimuscarinics, diphenoxylate)</td>
<td>adjunctive administration may potentiate GLP-1 agonist pharmacologic effects, including additional blood glucose reductions and hypoglycemia risk</td>
<td>use cautiously together</td>
<td>undetermined</td>
</tr>
</tbody>
</table>

*CP = Clinical Pharmacology

## 5 References


